KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Financing Activities (2016 - 2025)

Rigel Pharmaceuticals has reported Cash from Financing Activities over the past 16 years, most recently at -$4.6 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$4.6 million for Q4 2025, down 412.08% from a year ago — trailing twelve months through Dec 2025 was $601000.0 (up 105.16% YoY), and the annual figure for FY2025 was $601000.0, up 105.16%.
  • Cash from Financing Activities for Q4 2025 was -$4.6 million at Rigel Pharmaceuticals, down from $4.3 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for RIGL hit a ceiling of $59.2 million in Q2 2021 and a floor of -$9.8 million in Q3 2024.
  • Median Cash from Financing Activities over the past 5 years was $451000.0 (2025), compared with a mean of $3.8 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 1911.31% in 2022 and later plummeted 1032.57% in 2024.
  • Rigel Pharmaceuticals' Cash from Financing Activities stood at $1.1 million in 2021, then crashed by 293.18% to -$2.1 million in 2022, then skyrocketed by 123.19% to $486000.0 in 2023, then soared by 201.44% to $1.5 million in 2024, then tumbled by 412.08% to -$4.6 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$4.6 million (Q4 2025), $4.3 million (Q3 2025), and $418000.0 (Q2 2025) per Business Quant data.